# ASXL2

## Overview
ASXL2 (Additional Sex Combs Like 2) is a gene that encodes the ASXL transcriptional regulator 2 protein, which is a member of the ASXL family involved in chromatin remodeling and transcriptional regulation. The ASXL2 protein plays a critical role in gene expression by interacting with other proteins to modify histones, thereby influencing chromatin structure and gene expression. It is particularly significant in the regulation of hematopoiesis, acting as a haploinsufficient tumor suppressor in leukemia and being essential for the self-renewal of hematopoietic stem cells and the maintenance of hematopoietic progenitor cells (Micol2017ASXL2; Li2017Loss). ASXL2 is a component of the BAP1 deubiquitinase complex, where it facilitates the deubiquitination of histone H2A, a process crucial for cell cycle regulation and tumor suppression (Daou2015The). Mutations in ASXL2 are associated with various clinical conditions, including a unique neurodevelopmental syndrome and acute myeloid leukemia, particularly in cases with the RUNX1-RUNX1T1 fusion (Micol2017ASXL2; Shashi2016De).

## Structure
The ASXL2 protein is part of the ASXL family, which includes ASXL1 and ASXL3, and is involved in chromatin remodeling and transcriptional regulation. The ASXL2 protein contains several conserved domains, including the ASXN domain, ASXH domain, ASXM1 and ASXM2 domains, and a plant homeodomain (PHD) (Katoh2013Functional). The ASXN domain is a DNA-binding module, while the ASXH domain is involved in protein-protein interactions, particularly with epigenetic regulators like BAP1 (Katoh2013Functional; Dinan2017ASXL). The ASXM domains are also protein-protein interaction modules, associating with nuclear hormone receptors and their cofactors (Katoh2013Functional).

The ASXL2 protein's structure includes a highly conserved AB box within the ASXH domain, which is crucial for binding with BAP1 and stimulating its ubiquitin hydrolase activity (Peng2018Familial). This AB box is composed of five helices that form a stable conformation (Peng2018Familial). The PHD domain is involved in histone or DNA binding, although its specific targets in ASXL proteins are not yet identified (Katoh2013Functional).

ASXL2 may exist in multiple isoforms due to alternative splicing, which could lead to truncated forms of the protein lacking the C-terminal ASXM2 and PHD domains (Dinan2017ASXL). The protein is also subject to post-translational modifications such as phosphorylation and ubiquitination, which may affect its function.

## Function
ASXL2 (ASXL transcriptional regulator 2) is a gene that encodes a protein involved in chromatin remodeling and transcriptional regulation, playing a crucial role in gene expression by interacting with other proteins to modify histones. In healthy human cells, ASXL2 is essential for normal hematopoiesis, acting as a haploinsufficient tumor suppressor in leukemia. It is required for the self-renewal of hematopoietic stem cells (HSCs) and the maintenance of hematopoietic progenitor cells (HPCs), ensuring proper blood cell development and preventing hematopoietic defects (Micol2017ASXL2; Li2017Loss).

ASXL2 is part of the BAP1 deubiquitinase complex, where it promotes the assembly of a composite ubiquitin-binding interface necessary for the deubiquitination of histone H2A Lys-119. This process is vital for coordinating cell proliferation and preventing cancer development by maintaining normal cell cycle progression and histone modification (Daou2015The). The interaction between ASXL2 and BAP1 is crucial for cellular senescence and the activation of the p53/p21 tumor suppressor pathway, highlighting its role in tumor suppression (Daou2015The). ASXL2 is active in the nucleus, where it influences chromatin structure and gene expression, contributing to normal development and differentiation processes (Madan2018ASXL2).

## Clinical Significance
Mutations in the ASXL2 gene are associated with several clinical conditions. De novo truncating variants in ASXL2 have been linked to a unique neurodevelopmental syndrome characterized by developmental delay, macrocephaly, and distinct dysmorphic features. These features include prominent eyes, arched eyebrows, hypertelorism, a glabellar nevus flammeus, neonatal feeding difficulties, hypotonia, and variable intellectual disabilities. This condition is distinguished from other ASXL-related disorders by the presence of macrocephaly and the absence of growth retardation (Shashi2016De).

In the context of hematological malignancies, ASXL2 mutations are frequently found in patients with acute myeloid leukemia (AML), particularly those with the RUNX1-RUNX1T1 (AML1-ETO) fusion. These mutations often result in a loss of ASXL2 protein expression and act as a haploinsufficient tumor suppressor, promoting leukemogenesis. ASXL2 mutations are specifically enriched in AML with the AML1-ETO fusion and are not common in other forms of leukemia, suggesting a specific genetic interaction with AML1-ETO (Micol2017ASXL2; Yamato2017ASXL2).

The presence of ASXL2 mutations in AML patients with the t(8;21) translocation is associated with a distinct transcriptional profile and may influence the prognosis of the disease (Micol2014Frequent; Yamato2017ASXL2).

## Interactions
ASXL2 is involved in various protein interactions that are crucial for its function as an epigenetic regulator. It serves as a scaffold for the deubiquitinating enzyme BAP1, forming a complex that regulates histone H2A deubiquitination. This interaction is essential for maintaining the stability and function of both ASXL2 and BAP1, and disruptions in this complex are implicated in cancer progression (Daou2015The). ASXL2 competes with ASXL1 for binding to BAP1, and the presence of ASXL2 is necessary for the proper protein levels of BAP1 (Daou2015The).

ASXL2 also interacts with WTIP, a LIM domain-containing protein, which can inhibit ASXL2-mediated activation of retinoic acid signaling. This interaction is specific to the LIM domains of WTIP and is confirmed through various assays, including yeast two-hybrid and co-immunoprecipitation (Khan2014WTIP). The interaction between ASXL2 and WTIP plays a role in modulating retinoic acid signaling pathways, particularly during heart development (Khan2014WTIP).

ASXL2 is also known to interact with nuclear receptors, including the androgen and estrogen receptors, through its ASXM2 domain. These interactions are significant in the context of cancer development and progression (Katoh2015Functional).


## References


[1. (Micol2014Frequent) Jean-Baptiste Micol, Nicolas Duployez, Nicolas Boissel, Arnaud Petit, Sandrine Geffroy, Olivier Nibourel, Catherine Lacombe, Helene Lapillonne, Pascaline Etancelin, Martin Figeac, Aline Renneville, Sylvie Castaigne, Guy Leverger, Norbert Ifrah, Hervé Dombret, Claude Preudhomme, Omar Abdel-Wahab, and Eric Jourdan. Frequent asxl2 mutations in acute myeloid leukemia patients with t(8;21)/runx1-runx1t1 chromosomal translocations. Blood, 124(9):1445–1449, August 2014. URL: http://dx.doi.org/10.1182/blood-2014-04-571018, doi:10.1182/blood-2014-04-571018. This article has 98 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2014-04-571018)

[2. (Katoh2015Functional) Masaru Katoh. Functional proteomics of the epigenetic regulators asxl1, asxl2 and asxl3: a convergence of proteomics and epigenetics for translational medicine. Expert Review of Proteomics, 12(3):317–328, April 2015. URL: http://dx.doi.org/10.1586/14789450.2015.1033409, doi:10.1586/14789450.2015.1033409. This article has 46 citations and is from a peer-reviewed journal.](https://doi.org/10.1586/14789450.2015.1033409)

[3. (Dinan2017ASXL) Adam M. Dinan, John F. Atkins, and Andrew E. Firth. Asxl gain-of-function truncation mutants: defective and dysregulated forms of a natural ribosomal frameshifting product? Biology Direct, October 2017. URL: http://dx.doi.org/10.1186/s13062-017-0195-0, doi:10.1186/s13062-017-0195-0. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13062-017-0195-0)

[4. (Madan2018ASXL2) Vikas Madan, Lin Han, Norimichi Hattori, Weoi Woon Teoh, Anand Mayakonda, Qiao-Yang Sun, Ling-Wen Ding, Hazimah Binte Mohd Nordin, Su Lin Lim, Pavithra Shyamsunder, Pushkar Dakle, Janani Sundaresan, Ngan B. Doan, Masashi Sanada, Aiko Sato-Otsubo, Manja Meggendorfer, Henry Yang, Jonathan W. Said, Seishi Ogawa, Torsten Haferlach, Der-Cherng Liang, Lee-Yung Shih, Tsuyoshi Nakamaki, Q. Tian Wang, and H. Phillip Koeffler. Asxl2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion. Haematologica, 103(12):1980–1990, August 2018. URL: http://dx.doi.org/10.3324/haematol.2018.189928, doi:10.3324/haematol.2018.189928. This article has 14 citations.](https://doi.org/10.3324/haematol.2018.189928)

[5. (Micol2017ASXL2) Jean-Baptiste Micol, Alessandro Pastore, Daichi Inoue, Nicolas Duployez, Eunhee Kim, Stanley Chun-Wei Lee, Benjamin H. Durham, Young Rock Chung, Hana Cho, Xiao Jing Zhang, Akihide Yoshimi, Andrei Krivtsov, Richard Koche, Eric Solary, Amit Sinha, Claude Preudhomme, and Omar Abdel-Wahab. Asxl2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nature Communications, May 2017. URL: http://dx.doi.org/10.1038/ncomms15429, doi:10.1038/ncomms15429. This article has 57 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms15429)

[6. (Khan2014WTIP) Farida F. Khan, Yanyang Li, Arjun Balyan, and Q. Tian Wang. Wtip interacts with asxl2 and blocks asxl2-mediated activation of retinoic acid signaling. Biochemical and Biophysical Research Communications, 451(1):101–106, August 2014. URL: http://dx.doi.org/10.1016/j.bbrc.2014.07.080, doi:10.1016/j.bbrc.2014.07.080. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2014.07.080)

[7. (Li2017Loss) Jianping Li, Fuhong He, Peng Zhang, Shi Chen, Hui Shi, Yanling Sun, Ying Guo, Hui Yang, Na Man, Sarah Greenblatt, Zhaomin Li, Zhengyu Guo, Yuan Zhou, Lan Wang, Lluis Morey, Sion Williams, Xi Chen, Qun-Tian Wang, Stephen D. Nimer, Peng Yu, Qian-Fei Wang, Mingjiang Xu, and Feng-Chun Yang. Loss of asxl2 leads to myeloid malignancies in mice. Nature Communications, June 2017. URL: http://dx.doi.org/10.1038/ncomms15456, doi:10.1038/ncomms15456. This article has 19 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms15456)

[8. (Yamato2017ASXL2) Genki Yamato, Norio Shiba, Kenichi Yoshida, Yuichi Shiraishi, Yusuke Hara, Kentaro Ohki, Jun Okubo, Haruna Okuno, Kenichi Chiba, Hiroko Tanaka, Akitoshi Kinoshita, Hiroshi Moritake, Nobutaka Kiyokawa, Daisuke Tomizawa, Myoung‐ja Park, Manabu Sotomatsu, Takashi Taga, Souichi Adachi, Akio Tawa, Keizo Horibe, Hirokazu Arakawa, Satoru Miyano, Seishi Ogawa, and Yasuhide Hayashi. Asxl2 mutations are frequently found in pediatric aml patients with t(8;21)/ runx1‐runx1t1 and associated with a better prognosis. Genes, Chromosomes and Cancer, 56(5):382–393, February 2017. URL: http://dx.doi.org/10.1002/gcc.22443, doi:10.1002/gcc.22443. This article has 16 citations.](https://doi.org/10.1002/gcc.22443)

[9. (Katoh2013Functional) M Katoh. Functional and cancer genomics of asxl family members. British Journal of Cancer, 109(2):299–306, June 2013. URL: http://dx.doi.org/10.1038/bjc.2013.281, doi:10.1038/bjc.2013.281. This article has 116 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/bjc.2013.281)

[10. (Daou2015The) Salima Daou, Ian Hammond-Martel, Nazar Mashtalir, Haithem Barbour, Jessica Gagnon, NicholasV.G. Iannantuono, Nadine Sen Nkwe, Alena Motorina, Helen Pak, Helen Yu, Hugo Wurtele, Eric Milot, Frédérick A. Mallette, Michele Carbone, and El Bachir Affar. The bap1/asxl2 histone h2a deubiquitinase complex regulates cell proliferation and is disrupted in cancer. Journal of Biological Chemistry, 290(48):28643–28663, November 2015. URL: http://dx.doi.org/10.1074/jbc.m115.661553, doi:10.1074/jbc.m115.661553. This article has 100 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m115.661553)

[11. (Shashi2016De) Vandana Shashi, Loren D.M. Pena, Katherine Kim, Barbara Burton, Maja Hempel, Kelly Schoch, Magdalena Walkiewicz, Heather M. McLaughlin, Megan Cho, Nicholas Stong, Scott E. Hickey, Christine M. Shuss, Michael S. Freemark, Jane S. Bellet, Martha Ann Keels, Melanie J. Bonner, Maysantoine El-Dairi, Megan Butler, Peter G. Kranz, Constance T.R.M. Stumpel, Sylvia Klinkenberg, Karin Oberndorff, Malik Alawi, Rene Santer, Slavé Petrovski, Outi Kuismin, Satu Korpi-Heikkilä, Olli Pietilainen, Palotie Aarno, Mitja I. Kurki, Alexander Hoischen, Anna C. Need, David B. Goldstein, Fanny Kortüm, A. Bacino, Brendan H. Lee, Ashok Balasubramanyam, Lindsay C. Burrage, Gary D. Clark, William J. Craigen, Shweta U. Dhar, Lisa T. Emrick, Brett H. Graham, Mahim Jain, Seema R. Lalani, Richard A. Lewis, Paolo M. Moretti, Sarah K. Nicholas, Jordan S. Orange, Jennifer E. Posey, Lorraine Potocki, Jill A. Rosenfeld, Daryl A. Scott, Neil A. Hanchard, Tran A. Alyssa, Alejandro E. Mercedes, Azamian S. Mashid, Hugo J. Bellen, Shinya Yamamoto, Michael F. Wangler, Monte Westerfield, John H. Postlethwait, Christine M. Eng, Yaping Yang, Donna M. Muzny, Patricia A. Ward, Rachel B. Ramoni, Alexa T. McCray, Issac S. Kohane, Ingrid A. Holm, Matthew Might, Paul Mazur, Kimberly Splinter, Cecilia Esteves, Vandana Shashi, Yong-hui Jiang, Loren D.M. Pena, Allyn McConkie-Rosell, Kelly Schoch, Rebecca C. Spillmann, Jennifer A. Sullivan, Nicole M. Walley, David B. Goldstein, Nicholas Stong, Alan H. Beggs, Joseph Loscalzo, Calum A. MacRae, Edwin K. Silverman, Joan M. Stoler, David A. Sweetser, Richard L. Maas, Joel B. Krier, Lance H. Rodan, Chris A. Walsh, Cynthia M. Cooper, Juan C. Pallais, Laurel A. Donnell-Fink, Elizabeth L. Krieg, Sharyn A. Lincoln, Lauren C. Briere, Howard J. Jacob, Elizabeth A. Worthey, Joe Lazar, Kim A. Strong, Lori H. Handley, J. Scott Newberry, David P. Bick, Molly C. Schroeder, Donna M. Brown, Camille L. Birch, Shawn E. Levy, Braden E. Boone, Dan C. Dorset, Angela L. Jones, Teri A. Manolio, John J. Mulvihill, Anastasia L. Wise, Jyoti G. Dayal, David J. Eckstein, Donna M. Krasnewich, Carson R. Loomis, Laura A. Mamounas, Brenda Iglesias, Casey Martin, David M. Koeller, Thomas O. Metz, Euan A. Ashley, Paul G. Fisher, Jonathan A. Bernstein, Matt T. Wheeler, Patricia A. Zornio, Daryl M. Waggott, Annika M. Dries, Jennefer N. Kohler, Katrina M. Dipple, Stan F. Nelson, Christina G.S. Palmer, Eric Vilain, Patrick Allard, Esteban C. Dell Angelica, Hane Lee, Janet S. Sinsheimer, Jeanette C. Papp, Naghmeh Dorrani, Matthew R. Herzog, Hayk Barseghyan, David R. Adams, Christopher J. Adams, Elizabeth A. Burke, Katherine R. Chao, Mariska Davids, David D. Draper, Tyra Estwick, Trevor S. Frisby, Kate Frost, William A. Gahl, Valerie Gartner, Rena A. Godfrey, Mitchell Goheen, Gretchen A. Golas, Mary G. Gordon, Catherine A. Groden, Andrea L. Gropman, Mary E. Hackbarth, Isabel Hardee, Jean M. Johnston, Alanna E. Koehler, Lea Latham, Yvonne L. Latour, Chyau Yueh C. Lau, Paul R. Lee, Denise J. Levy, Adam P. Liebendorder, Ellen F. Macnamara, Valerie V. Maduro, May V. Malicdan, Thomas C. Markello, Alexandra J. McCarty, Jennifer L. Murphy, Michele E. Nehrebecky, Donna Novacic, Barbara N. Pusey, Sarah Sadozai, Katherine E. Schaffer, Prashant Sharma, Ariane G. Soldatos, Sara P. Thomas, Cynthia J. Tifft, Nathanial J. Tolman, Camilo Toro, Zaheer M. Valivullah, Colleen E. Wahl, Mike Warburton, Alec A. Weech, Lynne A. Wolfe, Guoyun Yu, Rizwan Hamid, John H. Newman, John A. Phillips, and Joy D. Cogan. De novo truncating variants in asxl2 are associated with a unique and recognizable clinical phenotype. The American Journal of Human Genetics, 99(4):991–999, October 2016. URL: http://dx.doi.org/10.1016/j.ajhg.2016.08.017, doi:10.1016/j.ajhg.2016.08.017. This article has 62 citations.](https://doi.org/10.1016/j.ajhg.2016.08.017)

[12. (Peng2018Familial) Hongzhuang Peng, Jeremy Prokop, Jayashree Karar, Kyewon Park, Li Cao, J. William Harbour, Anne M. Bowcock, S. Bruce Malkowicz, Mitchell Cheung, Joseph R. Testa, and Frank J. Rauscher. Familial and somatic bap1 mutations inactivate asxl1/2-mediated allosteric regulation of bap1 deubiquitinase by targeting multiple independent domains. Cancer Research, 78(5):1200–1213, February 2018. URL: http://dx.doi.org/10.1158/0008-5472.can-17-2876, doi:10.1158/0008-5472.can-17-2876. This article has 24 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.can-17-2876)